Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01959282




Registration number
NCT01959282
Ethics application status
Date submitted
7/10/2013
Date registered
10/10/2013
Date last updated
4/01/2019

Titles & IDs
Public title
A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis
Scientific title
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects With Moderately to Severely Active Ulcerative Colitis
Secondary ID [1] 0 0
54781532UCO2001
Secondary ID [2] 0 0
CR102640
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Colitis, Ulcerative 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - JNJ-54781532 25 mg once daily
Treatment: Drugs - JNJ-54781532 75 mg once daily
Treatment: Drugs - JNJ-54781532 150 mg once daily
Treatment: Drugs - JNJ-54781532 75 mg twice daily

Placebo comparator: Placebo - Participants will receive placebo once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive placebo through Week 32. Participants not in clinical response at Week 8 will receive treatment with 150 mg JNJ-54781532 orally once daily from Week 8 to Week 16. Participants who achieve a partial Mayo score response (ie, a change from baseline of =3 in the partial Mayo score) at Week 16 can continue receiving 150 mg JNJ-54781532 orally once daily through Week 32

Experimental: JNJ-54781532 25 mg once daily - Participants will receive 25 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of =3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 25 mg once daily through Week 32

Experimental: JNJ-54781532 75 mg once daily - Participants will receive 75 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of =3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg once daily through Week 32

Experimental: JNJ-54781532 150 mg once daily - Participants will receive 150 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of =3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 150 mg once daily through Week 32

Experimental: JNJ-54781532 75 mg twice daily - Participants will receive 75 mg of JNJ-54781532 twice daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of =3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg twice daily through Week 32


Treatment: Drugs: Placebo
Participants will receive placebo once daily

Treatment: Drugs: JNJ-54781532 25 mg once daily
Participants will receive 25 mg of JNJ-54781532 once daily

Treatment: Drugs: JNJ-54781532 75 mg once daily
Participants will receive 75 mg of JNJ-54781532 once daily

Treatment: Drugs: JNJ-54781532 150 mg once daily
Participants will receive 150 mg of JNJ-54781532 once daily

Treatment: Drugs: JNJ-54781532 75 mg twice daily
Participants will receive 75 mg of JNJ-54781532 twice daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline in the Mayo score at Week 8
Timepoint [1] 0 0
Week 8
Secondary outcome [1] 0 0
Number of participants with clinical response at Week 8
Timepoint [1] 0 0
Week 8
Secondary outcome [2] 0 0
Number of participants with clinical remission at Week 8
Timepoint [2] 0 0
Week 8
Secondary outcome [3] 0 0
Number of participants with mucosal healing at Week 8
Timepoint [3] 0 0
Week 8

Eligibility
Key inclusion criteria
* Have a clinical diagnosis of ulcerative colitis (UC) at least 3 months prior to screening
* Have moderately to severely active UC, defined as a baseline (Week 0) Mayo score of 6 to 12; including an endoscopy sub score greater than or equal to 2 as determined by a central read of the video endoscopy
* Current treatment with oral corticosteroids or have a history of failure to respond to, or tolerate, at least 1 of the following therapies oral corticosteroids (including budesonide), 6-mercaptopurine (6-MP), azathioprine (AZA), or anti- tumor necrosis factor therapy or be corticosteroid dependent (ie, an inability to successfully taper corticosteroids without a return of the symptoms of UC)
* Must discontinue 6-MP/AZA for at least 1 week before the first dose of study medication
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* At imminent risk for colectomy
* Have ulcerative colitis limited to the rectum only or to less than 20 centimeter of the colon
* Presence of a stoma
* Presence or history of a fistula
* History or current diagnosis of active or latent tuberculosis; human immunodeficiency virus; hepatitis C virus or hepatitis B virus infection; have had more than 1 herpes zoster infection or have had any diagnosis of disseminated herpes zoster
* Previous treatment with a janus kinase inhibitor (eg, tofacitinib)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/11/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
5/12/2015
Sample size
Target
Accrual to date
Final
219
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Bankstown
Recruitment hospital [2] 0 0
- Bedford
Recruitment hospital [3] 0 0
- Concord
Recruitment hospital [4] 0 0
- Herston
Recruitment hospital [5] 0 0
- Launceston
Recruitment hospital [6] 0 0
- Melbourne
Recruitment hospital [7] 0 0
- Penrith
Recruitment hospital [8] 0 0
- South Brisbane
Recruitment postcode(s) [1] 0 0
- Bankstown
Recruitment postcode(s) [2] 0 0
- Bedford
Recruitment postcode(s) [3] 0 0
- Concord
Recruitment postcode(s) [4] 0 0
- Herston
Recruitment postcode(s) [5] 0 0
- Launceston
Recruitment postcode(s) [6] 0 0
- Melbourne
Recruitment postcode(s) [7] 0 0
- Penrith
Recruitment postcode(s) [8] 0 0
- South Brisbane
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Michigan
Country [4] 0 0
United States of America
State/province [4] 0 0
Mississippi
Country [5] 0 0
United States of America
State/province [5] 0 0
New Jersey
Country [6] 0 0
United States of America
State/province [6] 0 0
North Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Ohio
Country [8] 0 0
United States of America
State/province [8] 0 0
Oklahoma
Country [9] 0 0
United States of America
State/province [9] 0 0
Tennessee
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
United States of America
State/province [11] 0 0
Virginia
Country [12] 0 0
United States of America
State/province [12] 0 0
Washington
Country [13] 0 0
Belgium
State/province [13] 0 0
Brussel
Country [14] 0 0
Belgium
State/province [14] 0 0
Gent
Country [15] 0 0
Belgium
State/province [15] 0 0
Kortrijk
Country [16] 0 0
Belgium
State/province [16] 0 0
Leuven
Country [17] 0 0
Bulgaria
State/province [17] 0 0
Pleven
Country [18] 0 0
Bulgaria
State/province [18] 0 0
Sofia
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Varna
Country [20] 0 0
Canada
State/province [20] 0 0
Alberta
Country [21] 0 0
Canada
State/province [21] 0 0
British Columbia
Country [22] 0 0
Canada
State/province [22] 0 0
Manitoba
Country [23] 0 0
Canada
State/province [23] 0 0
Ontario
Country [24] 0 0
Canada
State/province [24] 0 0
Quebec
Country [25] 0 0
France
State/province [25] 0 0
Lille Cedex
Country [26] 0 0
France
State/province [26] 0 0
Paris
Country [27] 0 0
France
State/province [27] 0 0
Pessac
Country [28] 0 0
Germany
State/province [28] 0 0
Berlin
Country [29] 0 0
Germany
State/province [29] 0 0
Essen
Country [30] 0 0
Germany
State/province [30] 0 0
Frankfurt A. M.
Country [31] 0 0
Germany
State/province [31] 0 0
Hannover
Country [32] 0 0
Germany
State/province [32] 0 0
Heidelberg
Country [33] 0 0
Germany
State/province [33] 0 0
Herne
Country [34] 0 0
Germany
State/province [34] 0 0
Jena
Country [35] 0 0
Germany
State/province [35] 0 0
Kiel
Country [36] 0 0
Germany
State/province [36] 0 0
Magdeburg
Country [37] 0 0
Germany
State/province [37] 0 0
Münster
Country [38] 0 0
Germany
State/province [38] 0 0
Neustadt
Country [39] 0 0
Germany
State/province [39] 0 0
Stade
Country [40] 0 0
Hungary
State/province [40] 0 0
Budapest N/A
Country [41] 0 0
Hungary
State/province [41] 0 0
Budapest
Country [42] 0 0
Hungary
State/province [42] 0 0
Békéscsaba
Country [43] 0 0
Hungary
State/province [43] 0 0
Mosonmagyarovar
Country [44] 0 0
Hungary
State/province [44] 0 0
Szekszárd
Country [45] 0 0
Israel
State/province [45] 0 0
Hadera
Country [46] 0 0
Israel
State/province [46] 0 0
Haifa
Country [47] 0 0
Israel
State/province [47] 0 0
Jerusalem
Country [48] 0 0
Israel
State/province [48] 0 0
Nazareth
Country [49] 0 0
Israel
State/province [49] 0 0
Ramat Gan
Country [50] 0 0
Israel
State/province [50] 0 0
Rechovot
Country [51] 0 0
Netherlands
State/province [51] 0 0
Amsterdam Zuidoost
Country [52] 0 0
Netherlands
State/province [52] 0 0
Amsterdam
Country [53] 0 0
Netherlands
State/province [53] 0 0
Maastricht
Country [54] 0 0
Netherlands
State/province [54] 0 0
Rotterdam
Country [55] 0 0
Poland
State/province [55] 0 0
Elblag
Country [56] 0 0
Poland
State/province [56] 0 0
Lodz
Country [57] 0 0
Poland
State/province [57] 0 0
Sopot
Country [58] 0 0
Poland
State/province [58] 0 0
Warszawa
Country [59] 0 0
Romania
State/province [59] 0 0
Bucharest
Country [60] 0 0
Romania
State/province [60] 0 0
Bucuresti
Country [61] 0 0
Romania
State/province [61] 0 0
Constanta
Country [62] 0 0
Romania
State/province [62] 0 0
Iasi
Country [63] 0 0
Romania
State/province [63] 0 0
Timisoara
Country [64] 0 0
Russian Federation
State/province [64] 0 0
Kazan N/A
Country [65] 0 0
Russian Federation
State/province [65] 0 0
Nizny Novgorod
Country [66] 0 0
Russian Federation
State/province [66] 0 0
Novosibirsk
Country [67] 0 0
Russian Federation
State/province [67] 0 0
Omsk
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Rostov-On-Don
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Ryazan
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Saint Petersburg
Country [71] 0 0
Russian Federation
State/province [71] 0 0
St Petersburg
Country [72] 0 0
Russian Federation
State/province [72] 0 0
St-Petersburg
Country [73] 0 0
Russian Federation
State/province [73] 0 0
Stavropol
Country [74] 0 0
Russian Federation
State/province [74] 0 0
Ufa
Country [75] 0 0
Russian Federation
State/province [75] 0 0
Yaroslavl
Country [76] 0 0
Ukraine
State/province [76] 0 0
Donetsk
Country [77] 0 0
Ukraine
State/province [77] 0 0
Ivano-Frankovsk
Country [78] 0 0
Ukraine
State/province [78] 0 0
Kharkiv
Country [79] 0 0
Ukraine
State/province [79] 0 0
Kiev
Country [80] 0 0
Ukraine
State/province [80] 0 0
Kiiev
Country [81] 0 0
Ukraine
State/province [81] 0 0
Kyiv
Country [82] 0 0
Ukraine
State/province [82] 0 0
Lviv
Country [83] 0 0
Ukraine
State/province [83] 0 0
Odessa
Country [84] 0 0
Ukraine
State/province [84] 0 0
Ternopil
Country [85] 0 0
Ukraine
State/province [85] 0 0
Uzhgorod
Country [86] 0 0
Ukraine
State/province [86] 0 0
Vinnitsa
Country [87] 0 0
Ukraine
State/province [87] 0 0
Zaporizhzhia
Country [88] 0 0
Ukraine
State/province [88] 0 0
Zhaporozhia 69104

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to evaluate dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).
Trial website
https://clinicaltrials.gov/study/NCT01959282
Trial related presentations / publications
Li K, Strauss R, Marano C, Greenbaum LE, Friedman JR, Peyrin-Biroulet L, Brodmerkel C, De Hertogh G. A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials. J Crohns Colitis. 2019 Aug 14;13(8):1025-1035. doi: 10.1093/ecco-jcc/jjz022.
Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, Zhang H, Strauss R, Szapary P, Johanns J, Panes J, Vermeire S, O'Brien CD, Yang Z, Bertelsen K, Marano C; Peficitinib-UC Study Group. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. J Crohns Colitis. 2018 Nov 9;12(10):1158-1169. doi: 10.1093/ecco-jcc/jjy085.
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01959282